BIT
IMDX

BlackRock Institutional Trust’s Insight Molecular Diagnostics IMDX Stock Holding History

BlackRock Institutional Trust’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$488K Hold
3,461
– – ﹤0.01% 3467
2016
Q3 		$349K Hold
3,461
– – ﹤0.01% 3548
2016
Q2 		$246K Sell
3,461
-1,186
-26% -$111K ﹤0.01% 3608
2016
Q1 		$428K Buy
+4,647
New +$412K ﹤0.01% 3489

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FM
Family Management New York $834M AUM 20.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

BlackRock Institutional Trust's IMDX Position: Q4 2016 in Review

BlackRock Institutional Trust held its Insight Molecular Diagnostics (IMDX) position steady in Q4 2016 at 3,461 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #3467.

BlackRock Institutional Trust first reported a position in IMDX in Q1 2016 and has held it in 4 quarters since. 32 funds tracked by Wall St. Rank hold IMDX as of Q4 2016.

  • BlackRock Institutional Trust held 3,461 shares of Insight Molecular Diagnostics worth $488K as of Q4 2016.
  • BlackRock Institutional Trust left its Insight Molecular Diagnostics share count unchanged in Q4 2016.
  • Insight Molecular Diagnostics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3467 holding.
  • BlackRock Institutional Trust first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 4 quarters since.
  • 32 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.